HUP1800129A1 - Compounds for selectively inhibiting myosin ii isoforms - Google Patents

Compounds for selectively inhibiting myosin ii isoforms

Info

Publication number
HUP1800129A1
HUP1800129A1 HUP1800129A HUP1800129A1 HU P1800129 A1 HUP1800129 A1 HU P1800129A1 HU P1800129 A HUP1800129 A HU P1800129A HU P1800129 A1 HUP1800129 A1 HU P1800129A1
Authority
HU
Hungary
Prior art keywords
isoforms
compounds
selectively inhibiting
inhibiting myosin
myosin
Prior art date
Application number
Other languages
Hungarian (hu)
Inventor
Andras Malnasi-Csizmadia
Mate Gyimesi
Andras Szabo
Peter Hari
Kumar Suthar Sharad
Mihaly Kovacs
Adam Istvan Horvath
Mate Penzes
Istvan Loerincz
Original Assignee
Printnet Kereskedelmi Es Szolgaltato Kft
Soneas Kutato Kft
Eoetvoes Lorand Tudomanyegyetem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Printnet Kereskedelmi Es Szolgaltato Kft, Soneas Kutato Kft, Eoetvoes Lorand Tudomanyegyetem filed Critical Printnet Kereskedelmi Es Szolgaltato Kft
Priority to HU1800129A priority Critical patent/HU231285B1/en
Priority to CN202311771677.0A priority patent/CN117924285A/en
Priority to MX2020011020A priority patent/MX2020011020A/en
Priority to BR112020021347-0A priority patent/BR112020021347A2/en
Priority to FIEP19779087.6T priority patent/FI3781263T3/en
Priority to EP19779087.6A priority patent/EP3781263B1/en
Priority to IL278105A priority patent/IL278105B2/en
Priority to HUE19779087A priority patent/HUE063424T2/en
Priority to CA3097479A priority patent/CA3097479A1/en
Priority to US17/048,206 priority patent/US11746112B2/en
Priority to AU2019256801A priority patent/AU2019256801A1/en
Priority to PCT/HU2019/050017 priority patent/WO2019202346A2/en
Priority to DK19779087.6T priority patent/DK3781263T3/en
Priority to ES19779087T priority patent/ES2963548T3/en
Priority to KR1020207033132A priority patent/KR20210010465A/en
Priority to PT197790876T priority patent/PT3781263T/en
Priority to SI201930626T priority patent/SI3781263T1/en
Priority to EP23184543.9A priority patent/EP4276102A3/en
Priority to CN201980040782.2A priority patent/CN112334191A/en
Priority to SG11202010177UA priority patent/SG11202010177UA/en
Priority to MA052298A priority patent/MA52298A/en
Priority to PL19779087.6T priority patent/PL3781263T3/en
Priority to JP2021506072A priority patent/JP7463344B2/en
Publication of HUP1800129A1 publication Critical patent/HUP1800129A1/en
Priority to PH12020551734A priority patent/PH12020551734A1/en
Publication of HU231285B1 publication Critical patent/HU231285B1/en
Priority to US18/345,772 priority patent/US11845758B2/en
Priority to JP2024050808A priority patent/JP2024075759A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU1800129A 2018-04-18 2018-04-18 Compounds for selectively inhibiting myosin ii isoforms HU231285B1 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
HU1800129A HU231285B1 (en) 2018-04-18 2018-04-18 Compounds for selectively inhibiting myosin ii isoforms
BR112020021347-0A BR112020021347A2 (en) 2018-04-18 2019-04-18 PHARMACEUTICALLY EFFECTIVE COMPOUNDS THAT SELECTIVELY INHIBITS MYOSIN 2 ISOFORMS
MA052298A MA52298A (en) 2018-04-18 2019-04-18 PHARMACEUTICALLY EFFECTIVE COMPOUNDS SELECTIVELY INHIBITING MYOSIN 2 ISOFORMS
ES19779087T ES2963548T3 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds that selectively inhibit myosin 2 isoforms
FIEP19779087.6T FI3781263T3 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
EP19779087.6A EP3781263B1 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
IL278105A IL278105B2 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
HUE19779087A HUE063424T2 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
CA3097479A CA3097479A1 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
US17/048,206 US11746112B2 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
AU2019256801A AU2019256801A1 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
PCT/HU2019/050017 WO2019202346A2 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
DK19779087.6T DK3781263T3 (en) 2018-04-18 2019-04-18 PHARMACEUTICALLY EFFECTIVE COMPOUNDS THAT SELECTIVELY INHIBIT THE MYOSIN-2 ISOFORMS
CN202311771677.0A CN117924285A (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds for selectively inhibiting myosin 2 isoforms
KR1020207033132A KR20210010465A (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds that selectively inhibit myosin 2 isoform
JP2021506072A JP7463344B2 (en) 2018-04-18 2019-04-18 Pharmaceutically Active Compounds That Selectively Inhibit Myosin 2 Isoform - Patent application
SI201930626T SI3781263T1 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
EP23184543.9A EP4276102A3 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
CN201980040782.2A CN112334191A (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds for selective inhibition of myosin 2 isoforms
SG11202010177UA SG11202010177UA (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
MX2020011020A MX2020011020A (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms.
PL19779087.6T PL3781263T3 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
PT197790876T PT3781263T (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
PH12020551734A PH12020551734A1 (en) 2018-04-18 2020-10-17 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
US18/345,772 US11845758B2 (en) 2018-04-18 2023-06-30 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
JP2024050808A JP2024075759A (en) 2018-04-18 2024-03-27 Pharmaceutically Active Compounds That Selectively Inhibit Myosin 2 Isoform - Patent application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1800129A HU231285B1 (en) 2018-04-18 2018-04-18 Compounds for selectively inhibiting myosin ii isoforms

Publications (2)

Publication Number Publication Date
HUP1800129A1 true HUP1800129A1 (en) 2019-10-28
HU231285B1 HU231285B1 (en) 2022-08-28

Family

ID=89992670

Family Applications (2)

Application Number Title Priority Date Filing Date
HU1800129A HU231285B1 (en) 2018-04-18 2018-04-18 Compounds for selectively inhibiting myosin ii isoforms
HUE19779087A HUE063424T2 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE19779087A HUE063424T2 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms

Country Status (21)

Country Link
US (2) US11746112B2 (en)
EP (2) EP4276102A3 (en)
JP (2) JP7463344B2 (en)
KR (1) KR20210010465A (en)
CN (2) CN112334191A (en)
AU (1) AU2019256801A1 (en)
BR (1) BR112020021347A2 (en)
CA (1) CA3097479A1 (en)
DK (1) DK3781263T3 (en)
ES (1) ES2963548T3 (en)
FI (1) FI3781263T3 (en)
HU (2) HU231285B1 (en)
IL (1) IL278105B2 (en)
MA (1) MA52298A (en)
MX (1) MX2020011020A (en)
PH (1) PH12020551734A1 (en)
PL (1) PL3781263T3 (en)
PT (1) PT3781263T (en)
SG (1) SG11202010177UA (en)
SI (1) SI3781263T1 (en)
WO (1) WO2019202346A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231285B1 (en) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. Compounds for selectively inhibiting myosin ii isoforms
CN112584832A (en) 2018-06-14 2021-03-30 斯克里普斯研究学院 Non-muscle myosin II inhibitors for substance use relapse

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT82752B (en) 1985-06-13 1988-12-15 Schering Corp PROCESS FOR THE PREPARATION OF POLYCYCLIC DERIVATIVES OF QUINOLINE, NAFTIRIDINE AND PYRAZINOPYRIDINE
US20110190270A1 (en) 2008-01-31 2011-08-04 Monash University Methods of treating thromboembolic disorders
WO2010120785A2 (en) 2009-04-13 2010-10-21 The Regents Of The University Of California Methods and compositions for stem cell cultures
AU2011250651B2 (en) 2010-05-05 2015-10-08 Genea Ip Holdings Pty Limited Media and methods for cell culture
EP2492687A1 (en) 2011-02-23 2012-08-29 Institut Gustave Roussy -Igr- MYH10 as a new diagnostic marker of pathologies resulting from RUNX1 inactivation
US9492441B2 (en) 2011-05-18 2016-11-15 Michael E. DiSanto Drug treatment of overactive bladder
US9994564B2 (en) 2011-05-18 2018-06-12 Michael E. DiSanto Myosin II ATPase inhibitor compounds
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
ES2602078T3 (en) 2013-03-15 2017-02-17 Lonza Cologne Gmbh Compositions and methods to improve the therapeutic potential of stem cells
CN106164287A (en) * 2014-02-18 2016-11-23 法国血液机构 High-resolution HLA typing
DK3277799T3 (en) 2015-04-03 2020-12-14 Propagenix Inc Ex vivo proliferation af epithelceller
US20180104692A1 (en) 2015-05-12 2018-04-19 Platod Combination of pharmacological and microfluidic features for improved platelets production
EP3529249A1 (en) 2016-01-29 2019-08-28 Paris Sciences et Lettres - Quartier Latin Water-soluble myosin 2 inhibitors for the treatment of neurological, neuropathic or psychiatric diseases
EP3755352A4 (en) 2018-02-20 2021-12-22 Edgewise Therapeutics, Inc. Methods and compositions for treating movement disorders
HU231285B1 (en) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. Compounds for selectively inhibiting myosin ii isoforms
CN112584832A (en) 2018-06-14 2021-03-30 斯克里普斯研究学院 Non-muscle myosin II inhibitors for substance use relapse
RS64828B1 (en) 2018-11-06 2023-12-29 Edgewise Therapeutics Inc Pyridazinone compounds and uses thereof

Also Published As

Publication number Publication date
EP3781263A2 (en) 2021-02-24
EP3781263B1 (en) 2023-07-12
PL3781263T3 (en) 2024-01-22
EP4276102A3 (en) 2023-12-06
EP4276102A2 (en) 2023-11-15
US11845758B2 (en) 2023-12-19
SI3781263T1 (en) 2024-01-31
US11746112B2 (en) 2023-09-05
CN117924285A (en) 2024-04-26
HU231285B1 (en) 2022-08-28
FI3781263T3 (en) 2023-09-15
US20210087201A1 (en) 2021-03-25
HUE063424T2 (en) 2024-01-28
CA3097479A1 (en) 2019-10-24
CN112334191A (en) 2021-02-05
WO2019202346A2 (en) 2019-10-24
IL278105A (en) 2020-12-31
WO2019202346A3 (en) 2019-12-19
MA52298A (en) 2021-02-24
IL278105B1 (en) 2024-01-01
KR20210010465A (en) 2021-01-27
PT3781263T (en) 2023-10-13
DK3781263T3 (en) 2023-10-02
US20230339959A1 (en) 2023-10-26
IL278105B2 (en) 2024-05-01
JP2021522322A (en) 2021-08-30
JP2024075759A (en) 2024-06-04
MX2020011020A (en) 2021-01-08
BR112020021347A2 (en) 2021-01-19
SG11202010177UA (en) 2020-11-27
PH12020551734A1 (en) 2021-06-07
ES2963548T3 (en) 2024-03-27
JP7463344B2 (en) 2024-04-08
AU2019256801A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
IL278116A (en) Pyridazinones as parp7 inhibitors
IL274540B (en) Compounds useful for inhibiting cdk7
IL277006A (en) Cd73 inhibitors
IL304348A (en) Cd73 inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
GB201819126D0 (en) Inhibitor compounds
PL3589637T3 (en) Compounds useful for inhibiting ror-gamma-t
HUP1800129A1 (en) Compounds for selectively inhibiting myosin ii isoforms
SI3589638T1 (en) Compounds useful for inhibiting ror-gamma-t
GB201707114D0 (en) Scale inhibition composition
PT3710446T (en) Compounds useful for inhibiting cdk7
GB201905370D0 (en) Elastate inhibition
GB201919095D0 (en) Inhibitory compounds
GB201917603D0 (en) Inhibitory compounds
GB201912603D0 (en) Inhibitory compounds
GB201904848D0 (en) Inhibitory compounds
GB201819136D0 (en) Inhibitor compounds
GB201806130D0 (en) Inhibitor compounds
GB201806131D0 (en) Inhibitor compounds

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: PRINTNET KERESKEDELMI ES SZOLGALTATO KFT., HU

Free format text: FORMER OWNER(S): SONEAS KUTATO KFT., HU; PRINTNET KERESKEDELMI ES SZOLGALTATO KFT., HU

Owner name: EOETVOES LORAND TUDOMANYEGYETEM, HU

Free format text: FORMER OWNER(S): SONEAS KUTATO KFT., HU; PRINTNET KERESKEDELMI ES SZOLGALTATO KFT., HU

Owner name: SONEAS KUTATO KFT., HU

Free format text: FORMER OWNER(S): SONEAS KUTATO KFT., HU; PRINTNET KERESKEDELMI ES SZOLGALTATO KFT., HU

GB9A Succession in title

Owner name: PRINTNET KERESKEDELMI ES SZOLGALTATO KFT., HU

Free format text: FORMER OWNER(S): SONEAS KUTATO KFT., HU; PRINTNET KERESKEDELMI ES SZOLGALTATO KFT., HU; PRINTNET KERESKEDELMI ES SZOLGALTATO KFT., HU; SONEAS KUTATO KFT., HU; EOETVOES LORAND TUDOMANYEGYETEM, HU

Owner name: EOETVOES LORAND TUDOMANYEGYETEM, HU

Free format text: FORMER OWNER(S): SONEAS KUTATO KFT., HU; PRINTNET KERESKEDELMI ES SZOLGALTATO KFT., HU; PRINTNET KERESKEDELMI ES SZOLGALTATO KFT., HU; SONEAS KUTATO KFT., HU; EOETVOES LORAND TUDOMANYEGYETEM, HU

FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

Representative=s name: SBGK SZABADALMI UEGYVIVOEI IRODA, HU

FH92 Termination of representative

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU